

- Glomerular diseases (*Continued*)  
 with glomerular basement membrane abnormalities, 326-327  
 glomerulonephritis, associated with HBV infection, 324  
 in intrinsic acute kidney injury, 358, 358.e1f  
 with nephritic syndrome, 317-320  
 with nephrotic syndrome, 315-317  
 from plasma cell dyscrasias, 323-324  
 with rapidly progressive glomerulonephritis, 320-323  
 thrombotic microangiopathies, 324-326
- Glomerular filtration rate (GFR), 286, 289  
 categories of, 363t  
 in chronic kidney disease, 291f, 363  
 estimation of, 292  
 hyperkalemia and, 305  
 rate of decline in, 367
- Glomerulonephritis, 284  
 acute kidney disease in, 352-353, 353f  
 acute proliferative, 358  
 anti-glomerular basement membrane antibody-mediated, 321, 322f  
 crescentic, 358.e1f  
 cryoglobulinemic, 322-323, 323t  
 fibrillary, 358  
 in Goodpasture's syndrome, 234  
 hepatitis B virus infection and, 324  
 infection-associated, 317-318, 318f  
 membranoproliferative, 319-320, 319f-320f  
 rapidly progressive, 315, 315f
- Glomerulosclerosis  
 diabetic, 328f  
 focal segmental, 316-317, 316f  
 causes of, 316t
- Glomerulus, 284  
 filtration in, 286  
 injury to, 314
- Glossopharyngeal neuralgia, 1000
- Glucagon-like peptide-1 (GLP-1) analogues, for type 2 diabetes, 666, 666t
- $\beta$ -D-glucan assays, 945
- Glucocorticoid deficiency  
 in adrenal insufficiency, 643, 645t  
 in congenital adrenal hyperplasia, 646
- Glucocorticoid excess, 647t. *see also* Cushing's syndrome.
- Glucocorticoid-remediable aldosteronism, 171
- Glucocorticoid-remediable hyperaldosteronism, 649
- Glucocorticoid replacement therapy, for adrenal insufficiency, 630
- Glucocorticoids, 642, 643f, 644t. *see also* Cortisol.  
 for hypercalcemia, cancer-associated, 620  
 for spinal cord compression, 619  
 for spondyloarthritis, 779  
 for superior vena cava syndrome, 619
- Gluconeogenesis, in kidneys, 287
- Glucosamine, for osteoarthritis, 807
- Glucose  
 cerebrospinal fluid, infection and, 856t, 861  
 impaired fasting, 657  
 impaired tolerance to, 657  
 with insulin, in hyperkalemia, 305-306  
 plasma, during fast, 671
- Glucose-6-phosphate dehydrogenase deficiency, 510-511
- Glucose-6-phosphate dehydrogenase (G6PD), 510-511
- Glucose-dependent insulinotropic peptide (GIP), 666-667
- Glucose intolerance, hypokalemia and, 304
- Glucose metabolism disorders, 1093-1094
- Glucose tolerance, impaired, 657
- Glucose tolerance test, in suspected neuropathy, 1083
- $\alpha$ -Glucosidase inhibitors, for type 2 diabetes, 666t, 667
- Glucotoxicity, 663
- Glutamine, parenteral nutrition and, 688
- $\gamma$ -Glutamyl transpeptidase (GGT), 440, 441t
- Gluten-sensitive enteropathy, 383
- Glycogen metabolism disorders, 1093-1094
- $\beta_2$ -glycoprotein I, antibodies against, 568, 570-571
- Glycoprotein IIb/IIIa, 534-535, 565, 565t  
 antibodies directed against, 550  
 fibrinogen and, 559  
 Glanzmann's thrombasthenia and, 556
- Glycoprotein IIb/IIIa inhibitors, in acute coronary syndrome, 102
- GM-CSF. *see* Granulocyte-macrophage colony-stimulating factor (GM-CSF).
- GnRH. *see* Gonadotropin-releasing hormone (GnRH).
- Goiter, 633, 639  
 in Graves' disease, 635-636  
 in Hashimoto's thyroiditis, 637, 639  
 in subclinical hypothyroidism, 639  
 toxic multinodular, 637
- Golimumab, for rheumatoid arthritis, 774t
- Gonadal failure, acquired, 653
- Gonadotropin-releasing hormone (GnRH), 625t, 631, 652, 652f  
 deficiency of, 653  
 for male infertility, 655
- Gonadotropin-secreting pituitary tumors, 626t, 631
- Gonadotropins, 631  
 deficiency of, 626t, 631  
 in male, 652, 652f  
 for male infertility, 655
- Gonorrhea, 919-920  
 clinical presentation of, 920  
 definition and epidemiology of, 919-920  
 diagnosis and differential diagnosis of, 920  
 pathology of, 920  
 prognosis of, 920  
 screening of women for, 702t  
 treatment of, 920
- Goodpasture's disease, 321
- Gorlin formula, 49
- Goserelin, for prostate cancer, 588
- Gout, 767t, 799-804  
 clinical features of, 800-801  
 diagnosis of, 801, 801f  
 differential diagnosis of, 801  
 epidemiology of, 799  
 pathogenesis of, 799-800  
 radiologic features of, 801  
 in transplantation patients, 801  
 treatment of
- Gout (*Continued*)  
 acute, 802  
 intercritical and chronic, 802-803
- Graft-versus-host disease (GVHD)  
 gastric involvement in, 413  
 in stem cell transplantation, 481, 588  
 vs. systemic sclerosis, 791t
- Graft-versus-leukemia effect, 481, 495
- Graft-versus-tumor effect, in stem cell transplantation, 588
- Granulocyte colony-stimulating factor (G-CSF)  
 with chemotherapy, 591  
 for neutropenia, 946
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 480, 517  
 with chemotherapy, 591  
 for fungal infections, 480-481
- Granulocytosis, 517
- Granuloma, formation of, macrophages in, 825
- Granuloma inguinale, 925
- Granulomatosis with polyangiitis (GPA), 320
- Granulomatous disorders, 743  
 in interstitial lung disease, 228-230
- Granulomatous thyroiditis, 637
- Graves' disease, 635-636, 639
- Gray platelet syndrome, 554t, 556
- Great arteries, transposition of, 74-75
- Great vessel injury, 146-147
- Ground-glass nodules, 268
- Group A streptococci, pharyngitis and, 868
- Growth factors, for myelodysplastic syndrome, 485-486
- Growth hormone (GH), 624, 625t-626t, 627-629  
 deficiency of, 626t, 627  
 hypersecretion of, 627-628, 628t
- Growth hormone-releasing hormone, 625t
- Guardianship, 1111-1112
- Guillain-Barré syndrome, 990, 1084-1085
- Gummas, 923
- Gynecoid obesity, 677
- Gynecomastia, 655-656, 655t, 656f
- ## H
- H1N1 influenza virus, 258
- Haemophilus influenzae* infection  
 meningitis in, 854  
 pneumonia in, 873-874, 874f
- Haldane effect, 213-214
- Hallucinations, visual, 1006  
 in diffuse Lewy body disease, 982
- Hallucinogens, 1129t-1130t, 1136
- Hamartin, 1031
- Hamartomas, lung, 595, 595.e2f
- Hamman's crunch, 188
- Hamman's sign, 188
- Hampton's hump, 166, 242
- Hand-foot syndrome, 621
- Haploid number, 2
- Haplotype, 7, 481
- Harris-Benedict equation, 684
- HAS-BLED score, 126
- Hashimoto's thyroiditis, 637
- Hashish, 1129t-1130t
- Hastened death, request for, 1121
- Hayflick phenomenon, 1103-1104
- HDL. *see* High-density lipoprotein (HDL).